Human Papillomavirus Infection
Conditions
Keywords
Gardasil, Prevalence-model, Cervarix, economic, health
Brief summary
This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and the quadrivalent HPV vaccine (HPV-2).
Detailed description
This study uses a prevalence-based model (by using efficacy data from each vaccine's respective trials and published cost data for Taiwan) which estimates the differences in lesions, genital warts, cervical cancer and costs from a healthcare payer's perspective prevented between HPV-1 and HPV-2 vaccines during one year (when all women are vaccinated). It also analyses costs from a societal perspective.
Interventions
OTHERPrevalence-based model
Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
Sponsors
GlaxoSmithKline
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
Yes
Inclusion criteria
* Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan (hypothetical group).
Exclusion criteria
* Not applicable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annual number of lesions prevented by each vaccine | Over a one-year period |
| Lesion related total cost averted by each vaccine | Over a one-year period |
| Additional costs averted by HPV-1 vaccine compared to HPV-2 vaccine | Over a one-year period |
Outcome results
None listed